Skip to main content
Signal8
Launch Terminal

HUTCHMED (China) Ltd (HCM)

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

HUTCHMED (China) Limited logo

HUTCHMED (China) Limited

NASDAQ:HCMHealthcare
-3.24%$13.15
AH$13.14-0.08%vs close
Mkt Cap$2.29B
Float170.46M
O/S173.81M
Vol
$ Vol
RVOL
Inst Own2.5%
SI0.2%
Earnings
Dilution
HUTCHMED (China) Limited logoNASDAQ:HCM$13.15-3.24%
Phase Distribution
50 lead-sponsored trials·12 active·27 completed
Phase 126
Phase 1/29
Phase 24
Phase 2/34
Phase 35
Not applicable2
(2 more as collaborator)
Status Overview
Recruiting10
Active, not recruiting2
Completed27
Stopped9
Expanded access1
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

    Savolitinib, Placebo

    Non-small Cell Lung Cancer

    Enrollment
    412
    Start
    Sep 2021
    Primary Completion
    May 2028est.
    Completion
    May 2028est.
    NCT05009836
  • Phase 3
    Completed

    Phase III Study on HMPL-523 for Treatment of ITP

    HMPL-523, Placebo

    Primary Immune Thrombocytopenia (ITP)

    Enrollment
    272
    Start
    Oct 2021
    Primary Completion
    May 2025
    Completion
    Sep 2025
    NCT05029635
  • Phase 3
    Recruiting

    A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

    HMPL-306 Regimen, Salvage Chemotherapy Regimen

    Acute Myeloid Leukemia

    Enrollment
    316
    Start
    Apr 2024
    Primary Completion
    Dec 2028est.
    Completion
    Sep 2029est.
    NCT06387069
  • Phase 3
    Recruiting

    Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

    fruquintinib, sintilimab

    Advanced Endometrial Cancer

    Enrollment
    412
    Start
    Dec 2024
    Primary Completion
    Jan 2029est.
    Completion
    Jun 2029est.
    NCT06584032
  • Phase 3
    Recruiting

    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

    HMPL-760, HMPL-760 Placebo

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Enrollment
    240
    Start
    Mar 2026
    Primary Completion
    Apr 2028est.
    Completion
    Dec 2028est.
    NCT07409428
  • Phase 2/3
    Recruiting

    HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

    HMPL-453

    Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult

    Enrollment
    235
    Start
    Sep 2020
    Primary Completion
    Jun 2028est.
    Completion
    Feb 2030est.
    NCT04353375
  • Phase 2/3
    Completed

    Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

    fruquintinib+sintilimab, axitinib / everolimus

    Advanced Renal Cell Carcinoma

    Enrollment
    265
    Start
    Oct 2022
    Primary Completion
    Aug 2026
    Completion
    Aug 2026
    NCT05522231
  • Phase 2/3
    Active, not recruiting

    HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

    HMPL-523(300mg PO QD), Placebo

    Warm Antibody Autoimmune Hemolytic Anemia

    Enrollment
    111
    Start
    Sep 2022
    Primary Completion
    Nov 2025
    Completion
    Nov 2026est.
    NCT05535933
  • Phase 2/3
    Recruiting

    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

    Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine

    Metastatic Pancreatic Cancer

    Enrollment
    502
    Start
    May 2024
    Primary Completion
    May 2028est.
    Completion
    May 2028est.
    NCT06361888
  • Phase 2
    Terminated

    Open-Label Surufatinib in European Patients With NET

    Surufatinib

    Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung +1

    Enrollment
    78
    Start
    Aug 2021
    Primary Completion
    Sep 2024
    Completion
    Oct 2024
    NCT04579679
  • Phase 2
    Completed

    Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

    Tazemetostat

    Relapsed/Refractory Follicular Lymphoma With EZH2

    Enrollment
    42
    Start
    Jul 2022
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT05467943
  • Phase 2
    Completed

    A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

    tazemetostat, HMPL-689

    Relapsed/Refractory Lymphoma

    Enrollment
    61
    Start
    Feb 2023
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT05713110
  • Phase 2
    Completed

    Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

    HMPL-760 planned dose 1, R-GemOx

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Enrollment
    61
    Start
    Nov 2024
    Primary Completion
    May 2026
    Completion
    May 2026
    NCT06601504
  • Phase 1/2
    Completed

    A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

    surufatinib

    Tumors

    Enrollment
    130
    Start
    Nov 2015
    Primary Completion
    Apr 2023
    Completion
    Jun 2023
    NCT02549937
  • Phase 1/2
    Completed

    : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

    Fruquintinib in Combination with Sintilimab

    Advanced Solid Tumor

    Enrollment
    348
    Start
    Apr 2019
    Primary Completion
    Nov 2023
    Completion
    Dec 2024
    NCT03903705
  • Phase 1/2
    Terminated

    A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

    Fruquintinib, Tislelizumab

    Triple Negative Breast Cancer, Endometrial Cancer +2

    Enrollment
    52
    Start
    Aug 2021
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT04577963
  • Phase 1/2
    Terminated

    Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

    Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2

    Metastatic Solid Tumor, Colorectal Cancer +5

    Enrollment
    87
    Start
    Mar 2021
    Primary Completion
    Apr 2024
    Completion
    Aug 2024
    NCT04579757
  • Phase 1/2
    Completed

    Open-label Study of Surufatinib in Japanese Patients

    Surufatinib

    Neuroendocrine Tumors, Non-hematologic Malignancy

    Enrollment
    36
    Start
    Sep 2021
    Primary Completion
    Sep 2024
    Completion
    Jan 2025
    NCT05077384
  • Phase 1/2
    Completed

    A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

    Surufatinib in combination with Gemcitabine

    Solid Tumor, Lymphoma +4

    Enrollment
    13
    Start
    Nov 2021
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT05093322
  • Phase 1/2
    Recruiting

    A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

    HMPL-A251, HMPL-A251

    Solid Tumors, Adult

    Enrollment
    147
    Start
    Dec 2025
    Primary Completion
    Nov 2028est.
    Completion
    Dec 2028est.
    NCT07228247
  • Phase 1/2
    Recruiting

    HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

    HMPL-A580, HMPL-A580

    Solid Tumors, Adult

    Enrollment
    186
    Start
    Mar 2026
    Primary Completion
    Dec 2028est.
    Completion
    Jan 2029est.
    NCT07396584
  • Phase 1/2
    Recruiting

    HMPL-A830 in Solid Tumors

    HMPL-A830, HMPL-A830

    Solid Tumor, Adult

    Enrollment
    147
    Start
    Sep 2026
    Primary Completion
    May 2029est.
    Completion
    Dec 2029est.
    NCT07718581
  • Phase 1
    Terminated

    An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

    HMPL-523

    Non Hodgkin Lymphoma

    Enrollment
    69
    Start
    Sep 2019
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT03779113
  • Phase 1
    Terminated

    Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

    HMPL-689

    Lymphoma

    Enrollment
    53
    Start
    Aug 2019
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT03786926
  • Phase 1
    Terminated

    A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

    HMPL-306

    Isocitrate Dehydrogenase Gene Mutation

    Enrollment
    42
    Start
    Feb 2021
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT04762602

1-25 of 50

Search ClinicalTrials.gov for “HUTCHMED (China)”